Scotia Capital’s DexCom DXCM Stock Holding History

Scotia Capital’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,672	Closed	-$502K	–	884
2021 Q3	$502K	Buy	+3,672	New	+$463K	﹤0.01%	622

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Scotia Capital's DXCM Position: Q4 2021 in Review

Scotia Capital sold out of DexCom (DXCM) in Q4 2021, closing a stake of 3,672 shares — an estimated $502K sold.

Scotia Capital first reported a position in DXCM in Q3 2021 and held it in 1 quarter. The position peaked at $502K in Q3 2021. 930 funds tracked by Wall St. Rank hold DXCM as of Q4 2021.

Scotia Capital reported no remaining DexCom position as of Q4 2021 after selling out during the quarter.
Scotia Capital sold 3,672 DexCom shares in Q4 2021, an estimated $502K.
Scotia Capital first reported a position in DexCom in Q3 2021 and held it in 1 quarter.
Scotia Capital's DexCom position peaked at $502K in Q3 2021.
930 funds tracked by Wall St. Rank held DexCom as of Q4 2021.

Based on Scotia Capital's 13F filing for Q4 2021, filed 11 Feb 2022.